Surgery Partners, Brentwood, TN

Surgery Partners

www.surgerypartners.com

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 180 locations in 31 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities.

Number of Employees: 5K-10K
Annual Revenue: > $1 Billion

www.surgerypartners.com
310 Seven Springs Way Suite 500
Brentwood, TN USA 37027
Phone: 615.234.5900

Name	Title	Contact Details
Spencer Clark	SVP and General Counsel	Profile
Roxanne Womack	SVP, Chief Compliance Officer	Profile
Spencer Clark	VP and Senior Legal Counsel	Profile
Kelly Whelan	VP and Senior Legal Counsel, American and Eastern Groups	Profile

Similar Companies

Frontage Laboratories

Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United States, China and other countries.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

CLOs on the Move